Prognostic significance of the bcl-2 apoptotic family of proteins in primary and recurrent cervical cancer

被引:61
作者
Crawford, RAF [1 ]
Caldwell, C [1 ]
Iles, RK [1 ]
Lowe, D [1 ]
Shepherd, JH [1 ]
Chard, T [1 ]
机构
[1] St Bartholomews Hosp, Dept Gynaecol, London EC1A 7BE, England
关键词
bcl-2; mcl-1; bax; p53; primary and recurrent cervical cancer;
D O I
10.1038/bjc.1998.466
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
bcl-2 is one of a family of genes that control the apoptotic threshold of a cell bcl-2 protein and its anti-apoptotic homologue, mcl-1, with the pro-apoptotic protein, bax, are thought to function by forming homo- and heterotypic dimers that then control the progression to apoptosis, p53 is also involved as a down-regulator of bcl-2 and a promoter of bax. To determine the effect of these apoptotic mechanisms, we used immunohistochemistry to determine the prognostic significance of the expression of bcl-2, mcl-1, bax and p53 in primary and recurrent cervical cancer. Tissues from 46 patients with primary cervical cancer and 28 women with recurrent carcinoma were stained for bcl-2, mcl-1, bax and p53, Kaplan-Meier survival analysis was performed using the log-rank test for differences between groups. In the primary disease group, positive staining for bcl-2 was associated with a better 5-year survival (bcl-2 +ve, 84% vs bcl-2 -ve, 53%, P = 0.03). Positive staining for p53 was associated with a survival disadvantage (p53 +ve, 4-year survival 38% vs p53 -ve, 4-year survival 78%, P = 0.02), mcl-1 and bax staining were not useful as prognostic indicators in primary disease. No marker was prognostic in recurrent disease. Positive bcl-2 staining defines a group of patients with primary disease with a good prognosis. p53, an activator of the bax promoter, identifies a group with a worse outcome. In recurrent disease, none of the markers reflected prognosis.
引用
收藏
页码:210 / 214
页数:5
相关论文
共 26 条
[1]  
HALDAR S, 1994, CANCER RES, V54, P2095
[2]  
Hall PA, 1996, J PATHOL, V180, P1
[3]   EXPRESSION AND PROGNOSTIC-SIGNIFICANCE OF BCL-2 IN OVARIAN-TUMORS [J].
HENRIKSEN, R ;
WILANDER, E ;
OBERG, K .
BRITISH JOURNAL OF CANCER, 1995, 72 (05) :1324-1329
[4]   BCL-2 IS AN INNER MITOCHONDRIAL-MEMBRANE PROTEIN THAT BLOCKS PROGRAMMED CELL-DEATH [J].
HOCKENBERY, D ;
NUNEZ, G ;
MILLIMAN, C ;
SCHREIBER, RD ;
KORSMEYER, SJ .
NATURE, 1990, 348 (6299) :334-336
[5]   A COMPARATIVE-STUDY OF THE PEROXIDASE-ANTIPEROXIDASE METHOD AND AN AVIDIN-BIOTIN COMPLEX METHOD FOR STUDYING POLYPEPTIDE HORMONES WITH RADIOIMMUNOASSAY ANTIBODIES [J].
HSU, SM ;
RAINE, L ;
FANGER, H .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1981, 75 (05) :734-738
[6]   p53 expression in carcinoma of the cervix [J].
Hunt, CR ;
Hale, RJ ;
Buckley, CH ;
Hunt, J .
JOURNAL OF CLINICAL PATHOLOGY, 1996, 49 (12) :971-974
[7]  
Kernohan NM, 1996, J PATHOL, V179, P1, DOI 10.1002/(SICI)1096-9896(199605)179:1<1::AID-PATH509>3.0.CO
[8]  
2-E
[9]  
KRAJEWSKI S, 1994, AM J PATHOL, V145, P515
[10]  
KRAJEWSKI S, 1995, AM J PATHOL, V146, P1309